Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

DRTS vs ARAY vs ISRG vs NVCR

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
DRTS
Alpha Tau Medical Ltd.

Biotechnology

HealthcareNASDAQ • IL
Market Cap$691M
5Y Perf.-18.7%
ARAY
Accuray Incorporated

Medical - Devices

HealthcareNASDAQ • US
Market Cap$35M
5Y Perf.-94.1%
ISRG
Intuitive Surgical, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$161.07B
5Y Perf.+84.1%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$1.92B
5Y Perf.-87.3%

DRTS vs ARAY vs ISRG vs NVCR — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
DRTS logoDRTS
ARAY logoARAY
ISRG logoISRG
NVCR logoNVCR
IndustryBiotechnologyMedical - DevicesMedical - Instruments & SuppliesMedical - Instruments & Supplies
Market Cap$691M$35M$161.07B$1.92B
Revenue (TTM)$0.00$429M$10.58B$674M
Net Income (TTM)$-43M$-46M$2.98B$-173M
Gross Margin26.8%66.3%75.2%
Operating Margin-5.1%30.5%-27.2%
Forward P/E43.8x
Total Debt$14M$176M$303M$290M
Cash & Equiv.$16M$57M$3.37B$103M

DRTS vs ARAY vs ISRG vs NVCRLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

DRTS
ARAY
ISRG
NVCR
StockMar 21May 26Return
Alpha Tau Medical L… (DRTS)10081.3-18.7%
Accuray Incorporated (ARAY)1005.9-94.1%
Intuitive Surgical,… (ISRG)100184.1+84.1%
NovoCure Limited (NVCR)10012.7-87.3%

Price return only. Dividends and distributions are not included.

Quick Verdict: DRTS vs ARAY vs ISRG vs NVCR

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ISRG leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Alpha Tau Medical Ltd. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
DRTS
Alpha Tau Medical Ltd.
The Momentum Pick

DRTS is the #2 pick in this set and the best alternative if momentum is your priority.

  • +188.6% vs ARAY's -78.4%
Best for: momentum
ARAY
Accuray Incorporated
The Specific-Use Pick

ARAY plays a supporting role in this comparison — it may shine differently against other peers.

Best for: healthcare exposure
ISRG
Intuitive Surgical, Inc.
The Income Pick

ISRG carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • beta 1.02
  • Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
  • 5.5% 10Y total return vs NVCR's 30.3%
  • Lower volatility, beta 1.02, Low D/E 1.7%, current ratio 4.87x
Best for: income & stability and growth exposure
NVCR
NovoCure Limited
The Secondary Option

NVCR lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
GrowthISRG logoISRG20.5% revenue growth vs DRTS's -115.8%
Quality / MarginsISRG logoISRG28.2% margin vs NVCR's -25.7%
Stability / SafetyISRG logoISRGBeta 1.02 vs ARAY's 2.42, lower leverage
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)DRTS logoDRTS+188.6% vs ARAY's -78.4%
Efficiency (ROA)ISRG logoISRG14.8% ROA vs DRTS's -42.3%, ROIC 15.0% vs -46.5%

DRTS vs ARAY vs ISRG vs NVCR — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

DRTSAlpha Tau Medical Ltd.

Segment breakdown not available.

ARAYAccuray Incorporated
FY 2025
Product
51.8%$238M
Service
48.2%$221M
ISRGIntuitive Surgical, Inc.
FY 2025
Instruments and Accessories
59.8%$6.0B
Systems
24.6%$2.5B
Services
15.6%$1.6B
NVCRNovoCure Limited

Segment breakdown not available.

DRTS vs ARAY vs ISRG vs NVCR — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLISRGLAGGINGNVCR

Income & Cash Flow (Last 12 Months)

ISRG leads this category, winning 5 of 6 comparable metrics.

ISRG and DRTS operate at a comparable scale, with $10.6B and $0 in trailing revenue. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricDRTS logoDRTSAlpha Tau Medical…ARAY logoARAYAccuray Incorpora…ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure Limited
RevenueTrailing 12 months$0$429M$10.6B$674M
EBITDAEarnings before interest/tax$18M-$15M$3.8B-$165M
Net IncomeAfter-tax profit-$43M-$46M$3.0B-$173M
Free Cash FlowCash after capex-$33M-$28M$2.8B-$48M
Gross MarginGross profit ÷ Revenue+26.8%+66.3%+75.2%
Operating MarginEBIT ÷ Revenue-5.1%+30.5%-27.2%
Net MarginNet income ÷ Revenue-10.8%+28.2%-25.7%
FCF MarginFCF ÷ Revenue-6.5%+26.8%-7.1%
Rev. Growth (YoY)Latest quarter vs prior year-7.4%+23.0%+12.3%
EPS Growth (YoY)Latest quarter vs prior year0.0%-6.1%+18.8%-100.0%
ISRG leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

ARAY leads this category, winning 4 of 4 comparable metrics.

On an enterprise value basis, ARAY's 11.0x EV/EBITDA is more attractive than ISRG's 43.6x.

MetricDRTS logoDRTSAlpha Tau Medical…ARAY logoARAYAccuray Incorpora…ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure Limited
Market CapShares × price$691M$35M$161.1B$1.9B
Enterprise ValueMkt cap + debt − cash$689M$154M$158.0B$2.1B
Trailing P/EPrice ÷ TTM EPS-14.81x-18.91x57.62x-13.80x
Forward P/EPrice ÷ next-FY EPS est.43.84x
PEG RatioP/E ÷ EPS growth rate2.65x
EV / EBITDAEnterprise value multiple10.99x43.62x
Price / SalesMarket cap ÷ Revenue0.08x16.00x2.92x
Price / BookPrice ÷ Book value/share8.20x0.37x9.17x5.51x
Price / FCFMarket cap ÷ FCF64.67x
ARAY leads this category, winning 4 of 4 comparable metrics.

Profitability & Efficiency

ISRG leads this category, winning 7 of 9 comparable metrics.

ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-77 for ARAY. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to ARAY's 2.17x. On the Piotroski fundamental quality scale (0–9), ARAY scores 6/9 vs DRTS's 3/9, reflecting solid financial health.

MetricDRTS logoDRTSAlpha Tau Medical…ARAY logoARAYAccuray Incorpora…ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure Limited
ROE (TTM)Return on equity-57.3%-77.5%+16.9%-50.8%
ROA (TTM)Return on assets-42.3%-10.1%+14.8%-16.5%
ROICReturn on invested capital-46.5%+3.0%+15.0%-16.4%
ROCEReturn on capital employed-48.7%+2.8%+16.5%-28.9%
Piotroski ScoreFundamental quality 0–93665
Debt / EquityFinancial leverage0.18x2.17x0.02x0.85x
Net DebtTotal debt minus cash-$2M$119M-$3.1B$187M
Cash & Equiv.Liquid assets$16M$57M$3.4B$103M
Total DebtShort + long-term debt$14M$176M$303M$290M
Interest CoverageEBIT ÷ Interest expense-100.93x-1.86x-96.80x
ISRG leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

DRTS leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in ISRG five years ago would be worth $15,873 today (with dividends reinvested), compared to $606 for ARAY. Over the past 12 months, DRTS leads with a +188.6% total return vs ARAY's -78.4%. The 3-year compound annual growth rate (CAGR) favors DRTS at 35.6% vs ARAY's -56.6% — a key indicator of consistent wealth creation.

MetricDRTS logoDRTSAlpha Tau Medical…ARAY logoARAYAccuray Incorpora…ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure Limited
YTD ReturnYear-to-date+62.5%-65.5%-19.3%+28.3%
1-Year ReturnPast 12 months+188.6%-78.4%-15.4%+1.1%
3-Year ReturnCumulative with dividends+149.2%-91.8%+49.6%-75.7%
5-Year ReturnCumulative with dividends-19.2%-93.9%+58.7%-91.3%
10-Year ReturnCumulative with dividends-22.3%-94.5%+554.2%+30.3%
CAGR (3Y)Annualised 3-year return+35.6%-56.6%+14.4%-37.6%
DRTS leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — DRTS and ISRG each lead in 1 of 2 comparable metrics.

ISRG is the less volatile stock with a 1.02 beta — it tends to amplify market swings less than ARAY's 2.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DRTS currently trades 86.5% from its 52-week high vs ARAY's 14.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricDRTS logoDRTSAlpha Tau Medical…ARAY logoARAYAccuray Incorpora…ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure Limited
Beta (5Y)Sensitivity to S&P 5001.72x2.42x1.02x2.20x
52-Week HighHighest price in past year$9.07$2.10$603.88$20.06
52-Week LowLowest price in past year$2.57$0.28$427.84$9.82
% of 52W HighCurrent price vs 52-week peak+86.5%+14.0%+75.1%+83.9%
RSI (14)Momentum oscillator 0–10049.458.442.469.8
Avg Volume (50D)Average daily shares traded328K1.4M1.8M1.5M
Evenly matched — DRTS and ISRG each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: DRTS as "Buy", ISRG as "Buy", NVCR as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs 37.3% for ISRG (target: $623).

MetricDRTS logoDRTSAlpha Tau Medical…ARAY logoARAYAccuray Incorpora…ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure Limited
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$12.00$622.60$33.50
# AnalystsCovering analysts45515
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+1.4%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ISRG leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ARAY leads in 1 (Valuation Metrics). 1 tied.

Best OverallIntuitive Surgical, Inc. (ISRG)Leads 2 of 6 categories
Loading custom metrics...

DRTS vs ARAY vs ISRG vs NVCR: Key Questions Answered

9 questions · data-driven answers · updated daily

01

Is DRTS or ARAY or ISRG or NVCR a better buy right now?

For growth investors, Intuitive Surgical, Inc.

(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus 2. 7% for Accuray Incorporated (ARAY). Intuitive Surgical, Inc. (ISRG) offers the better valuation at 57. 6x trailing P/E (43. 8x forward), making it the more compelling value choice. Analysts rate Alpha Tau Medical Ltd. (DRTS) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — DRTS or ARAY or ISRG or NVCR?

Over the past 5 years, Intuitive Surgical, Inc.

(ISRG) delivered a total return of +58. 7%, compared to -93. 9% for Accuray Incorporated (ARAY). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus ARAY's -94. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — DRTS or ARAY or ISRG or NVCR?

By beta (market sensitivity over 5 years), Intuitive Surgical, Inc.

(ISRG) is the lower-risk stock at 1. 02β versus Accuray Incorporated's 2. 42β — meaning ARAY is approximately 138% more volatile than ISRG relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 2% for Accuray Incorporated — giving it more financial flexibility in a downturn.

04

Which is growing faster — DRTS or ARAY or ISRG or NVCR?

By revenue growth (latest reported year), Intuitive Surgical, Inc.

(ISRG) is pulling ahead at 20. 5% versus 2. 7% for Accuray Incorporated (ARAY). On earnings-per-share growth, the picture is similar: Accuray Incorporated grew EPS 90. 3% year-over-year, compared to -17. 8% for Alpha Tau Medical Ltd.. Over a 3-year CAGR, ISRG leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — DRTS or ARAY or ISRG or NVCR?

Intuitive Surgical, Inc.

(ISRG) is the more profitable company, earning 28. 4% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is DRTS or ARAY or ISRG or NVCR more undervalued right now?

Analyst consensus price targets imply the most upside for NVCR: 99.

0% to $33. 50.

07

Which pays a better dividend — DRTS or ARAY or ISRG or NVCR?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

08

Is DRTS or ARAY or ISRG or NVCR better for a retirement portfolio?

For long-horizon retirement investors, Intuitive Surgical, Inc.

(ISRG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 02), +554. 2% 10Y return). Accuray Incorporated (ARAY) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ISRG: +554. 2%, ARAY: -94. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between DRTS and ARAY and ISRG and NVCR?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DRTS is a small-cap quality compounder stock; ARAY is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

DRTS

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ARAY

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 16%
Run This Screen
Stocks Like

ISRG

High-Growth Quality Leader

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Net Margin > 16%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.